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Purpose: The purpose of this study is to report a case of bilateral acute retinal necrosis in a patient with multiple
sclerosis treated with natalizumab.
Methods: This study is a case report and literature review.
Results: A 34-year-old Caucasian female with multiple sclerosis presented with 1 week of blurry vision in both eyes
during treatment with natalizumab. Clinical examination revealed bilateral acute retinal necrosis. The patient was
treated with systemic intravenous acyclovir and intravitreal injections foscarnet and ganciclovir. Natalizumab therapy
was also discontinued.
Conclusions: Natalizumab is a potent immunosuppressive agent used in relapsing remitting multiple sclerosis and
Crohn’s disease. The use of this medication is commonly associated with opportunistic infections in the CNS. In rare
cases, ocular opportunistic infections may occur and can lead to significant visual impairment and blindness.
Neurologists and ophthalmologists should be aware of this potential complication.
Keywords: Herpes virus, Immunosuppression, Multiple sclerosis, Natalizumab, Retinal necrosisAcute retinal necrosis (ARN) is a rare infectious uveitis
that is caused by members of the herpes family including
varicella zoster virus (VZV), herpes simplex virus (HSV),
cytomegalovirus (CMV), and less frequently Epstein-Barr
virus (EBV) [1]. The syndrome is characterized by necro-
tizing retinitis that can lead to severe visual impairment
and blindness, even despite prompt diagnosis and man-
agement [2, 3]. Here, we present a unique case of bilateral
ARN in patient with multiple sclerosis on natalizumab
immunosuppression.Case report
A 34-year-old Caucasian female presented to the Emory
Eye Center in March 2015 with complaints of blurry
vision in both eyes for the past 1 week. The patient’s
past medical history is notable for multiple sclerosis
(MS) diagnosed in 2011 after an episode of bilateral
optic neuritis and gait instability. Her MS was initially
managed with interferon beta-1a in 2011, but due to re-
current flares, she was transitioned to natalizumab in* Correspondence: arjunbsood@gmail.com
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the Creative Commons license, and indicate if2012. She had received monthly infusions of natalizumab
with the last infusion 3 weeks prior to presentation.
Visual acuity was 20/25 right and 20/50 eccentrically left
eye. The pupils were equal and reactive without a rela-
tive afferent pupillary defect. Intraocular pressures were
14 in both eyes. Extraocular motility was full and non-
painful in both eyes. Anterior segment exam was notable
for trace cell in the right eye and 2 + cell in the left eye.
Funduscopic examination showed areas of retinal whit-
ening in the macula and periphery in both eyes with
more confluent areas of necrosis in the left eye associ-
ated with retinal hemorrhage (Fig. 1a, b).
The patient’s clinical presentation was consistent
with bilateral acute retinal necrosis, and she was ad-
mitted for further evaluation and management. A
diagnostic anterior chamber (AC) paracentesis was
performed, and the sample was tested for VZV, HSV,
CMV, and toxoplasmosis PCR. The patient was given
intravitreal injections of foscarnet 2.4 mg/0.1 cm3 and
ganciclovir 2 mg/0.1 cm3 in both eyes and adminis-
tered intravenous acyclovir. The diagnostic AC para-
centesis was positive for VZV, and systemic work-up
was unrevealing for HIV. Magnetic resonanceis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Funduscopic examination showed areas of retinal whitening in the macula and periphery in the right eye (a) and left eye (b) with more
confluent areas of necrosis in the left eye associated with retinal hemorrhage
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litis. After consultation with neurology, natalizumab
was discontinued. Over the next several months, the
patient was given multiple bilateral intravitreal injec-
tions and continued on systemic oral valacyclovir 1 g
three times a day. The infection in the right eye re-
solved, and she maintained good vision at 20/30 at
the last follow-up. However, despite aggressive ther-
apy, the retinitis in the left eye rapidly spread
throughout the macula and went on to involve the
optic nerve with a drop in vision to hand motion.
The patient later developed a macular-sparing com-
bined tractional and rhegmatogenous retinal detach-
ment in the left eye. Four months after presentation,
the patient underwent scleral buckling and pars plana
vitrectomy with silicon oil and successful reattach-
ment of the retina. Visual acuity in the left eye at thelast follow-up was hand motion, limited by macular
and optic atrophy. The patient remains off natalizu-
mab and is taking oral valacyclovir 1 g daily.
Discussion
The case presented herein represents an atypical presen-
tation of acute retinal necrosis. ARN is an infectious
uveitis caused by members of the herpes family. The
syndrome is characterized by necrotizing retinitis, vitri-
tis, occlusive vasculitis, and rapid progression in the ab-
sence of antiviral therapy [3]. ARN is a rare ocular
condition and the exact incidence in the USA is un-
known; however, evidence from the UK in 2007 esti-
mates an incidence of one case per 1.6 to two million
population per year [4].
Risk factors for the development of ARN include recent
herpes virus infection, genetic predisposition, and history
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been associated with the development of ARN [5].
More recently, natalizumab has been implicated in
the development of herpetic retinal necrosis [6–8].
Natalizumab is a humanized monoclonal antibody
used in the treatment of relapsing and remitting MS
and Crohn’s disease [9].
Natalizumab binds to the alpha-4 subunit of integrins
expressed on leukocytes and interferes with their ability
to adhere to endothelial cells and migrate into the cen-
tral nervous system and gastrointestinal tract. In patients
with MS, natalizumab decreases the CD4+/CD8+ ratio
in the CSF compared to peripheral blood resulting in
impaired immune surveillance [9, 10]. Patients on natali-
zumab are at risk for opportunistic infections. The most
feared infection is progressive multifocal leukoencepha-
lopathy caused by the JC virus. Recent reports by the US
Food and Drug Administration (FDA) and others sug-
gest a growing association with herpes-related infections
in the CNS and eye [10].
Table 1 illustrates the three previously reported cases
of herpetic retinal necrosis in patients receiving natali-
zumab [6–8]. All patients discontinued natalizumab,
and one case utilized plasma exchange to accelerate
natalizumab clearance. All patients received systemic
antivirals.Table 1 Clinical characteristics and visual outcomes in patients with
Publication Age (years) Sex
Kobeleva et al. 49 M
Saraiva 51 M
Van Tassel et al. 54 F
Current study 34 F
Publication Initial VA Treatment/clinical course
Kobeleva et al. Not reported CNS vasculitis and necrotizing r
with combination of IV acyclovi
methylprednisone and 5 cycles
exchange therapy to accelerate
clearance.
Cyclophosphamide was given a
and plasma exchange.
Saraiva 20/30 OD Natalizumab was discontinued.
1 g TID for 3 months. Oral pred
4 days after starting valacyclovir
laser retinal photocoagulation p
after initiation of antiviral therap
discontinuing antiviral therapy,
developed immune reconstituti
syndrome. Systemic steroids res
Van Tassel et al. 20/125 OS Natalizumab was discontinued.
antivirals were administered. Co
retinal detachment.
Current study 20/25 OD, 20/50 OS Natalizumab was discontinued.
antivirals were administered. Co
retinal detachment and optic atOur patient was treated with systemic intravenous and
oral antivirals and intravitreal injections of foscarnet
(2.4 mg/0.1 cm3) and ganciclovir (2 mg/0.1 cm3). Despite
appropriate therapy, our patient developed a com-
bined tractional and rhegmatogenous retinal detach-
ment in the left eye. She underwent scleral buckling
and pars plana vitrectomy with silicon oil with suc-
cessful reattachment of the retina. However, vision re-
mains hand motion at the last follow-up due to
macular and optic nerve involvement of the necrotiz-
ing retinitis. The right eye was successfully treated
and vision remained 20/30.Conclusions
Acute retinal necrosis is a rare infectious uveitis that can
lead to significant visual impairment and blindness des-
pite prompt diagnosis and management. Patients with
history of natalizumab immunosuppression must be
treated aggressively. We recommend discontinuation of
natalizumab and intensive treatment with antivirals. As
with other cases of ARN, there is a high risk of retinal
detachment and severe vision loss. Consideration should
be given to plasma exchange therapy to accelerate natali-
zumab clearance but should be done only in coordin-
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11 months 20/30 OD, HM OS
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